XJPX
4527
Market cap3.87bUSD
Oct 09, Last price
2,693.00JPY
1D
-0.54%
1Q
10.82%
Jan 2017
193.04%
Name
Rohto Pharmaceutical Co Ltd
Chart & performance
P/E
17.77
P/S
1.77
EPS
151.56
Div yield, %
1.51%
Shrs. gr., 5y
0.58%
Rev. gr., 5y
13.68%
Revenues
343.73b
+11.37%
Net income
34.25b
+10.46%
CFO
47.79b
+29.45%
Dividend
Mar 30, 202725 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
Key people
Kunio Yamada
Chairman of the Board, Chief Executive Officer, Chairman of Subsidiary, Representative Director · since 2019
Hidetoshi Segi
President, Chief Operating Officer, Representative Director · since 2025
Masashi Sugimoto
President, Chief Operating Officer, Chairman of Subsidiary, Representative Director · since 2021
Chief Human Resources Officer, Director · since 2023
Yoko Fujimoto
Managing Director, Chief Medical Officer · since 2025
Yoichi Homma
Chief Scientific Officer, Director · since 2024
Masae Yamanaka
Chief Transformation Officer, Director · since 2024
Shinichi Kunisaki
Vice President, Chief Technology Officer, Director · since 2023
Masaya Saito
Vice President, Chief Financial Officer, Chairman and President of Subsidiaries, Director · since 2022
Eriko Hayashi
Independent Director · since 2022
Independent Director · since 2019
Independent Director · since 2025
Maiko Katadae
Independent Director · since 2024
Haruka Mera
Independent Director · since 2020
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||